PARIS--A new venture capital investment fund, Auriga, was launched last week with plans to invest half of its $400 million in startup capital in life sciences companies, including businesses in genomics and biotechnology. The other half of the fund will be dedicated to information technology, the fund's managers announced. The fund aims to become a benchmark in Europe for financing new high-tech companies, they said.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.